Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mark

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
The Journal of Laboratory and Clinical Medicine|January 10, 2004
Impairment of blood rheology by cholestatic jaundice in human beingsMichael Mark, Roland Walter, John Contesse, et al.
BMJ Case Reports|November 5, 2020
Amiodarone-induced neuromyopathy in a geriatric patientMichael Mark Stanton, Leyla Samii, Gentson Leung, et al.
International Journal of Cardiology|January 6, 2012
The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in ratsBerthold Hocher, Yuliya Sharkovska, Michael Mark, et al.
Diabetes Research and Clinical Practice|July 22, 2018
Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptinGerd Luippold, Michael Mark, Thomas Klein, et al.
Journal of the National Cancer Institute|December 1, 2021
RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate CancerMichael Mark, Roger von Moos, Richard Cathomas, et al.
Physical Review Letters|October 4, 2003
Three-body recombination at large scattering lengths in an ultracold atomic gasTino Weber, Jens Herbig, Michael Mark, et al.
Science (New York, N.Y.)|December 10, 2002
Bose-Einstein condensation of cesiumTino Weber, Jens Herbig, Michael Mark, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2008
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitorsLeo Thomas, Matthias Eckhardt, Elke Langkopf, et al.
Anesthesia and Analgesia|May 28, 2005
The influence of two different hydroxyethyl starch solutions (6% HES 130/0.4 and 200/0.5) on blood viscosityThomas A Neff, Lukas Fischler, Michael Mark, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 14, 2010
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitisDetlef Schuppan, Mark D Gorrell, Thomas Klein, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
The Journal of Laboratory and Clinical Medicine|January 10, 2004
Impairment of blood rheology by cholestatic jaundice in human beingsMichael Mark, Roland Walter, John Contesse, et al.
BMJ Case Reports|November 5, 2020
Amiodarone-induced neuromyopathy in a geriatric patientMichael Mark Stanton, Leyla Samii, Gentson Leung, et al.
International Journal of Cardiology|January 6, 2012
The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in ratsBerthold Hocher, Yuliya Sharkovska, Michael Mark, et al.
Diabetes Research and Clinical Practice|July 22, 2018
Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptinGerd Luippold, Michael Mark, Thomas Klein, et al.
Journal of the National Cancer Institute|December 1, 2021
RE: Real-World Use of Bone Modifying Agents in Metastatic Castration-Sensitive Prostate CancerMichael Mark, Roger von Moos, Richard Cathomas, et al.
Physical Review Letters|October 4, 2003
Three-body recombination at large scattering lengths in an ultracold atomic gasTino Weber, Jens Herbig, Michael Mark, et al.
Science (New York, N.Y.)|December 10, 2002
Bose-Einstein condensation of cesiumTino Weber, Jens Herbig, Michael Mark, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 29, 2008
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitorsLeo Thomas, Matthias Eckhardt, Elke Langkopf, et al.
Anesthesia and Analgesia|May 28, 2005
The influence of two different hydroxyethyl starch solutions (6% HES 130/0.4 and 200/0.5) on blood viscosityThomas A Neff, Lukas Fischler, Michael Mark, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 14, 2010
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitisDetlef Schuppan, Mark D Gorrell, Thomas Klein, et al.
Pageof 9